Reductions in Absolute PASI Over 144 Weeks of Treatment With Certolizumab Pegol in Patients With Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin 2020, 4 (6), s84. https://doi.org/10.25251/skin.4.supp.84.